Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2026-01-05 @ 1:14 PM
Study NCT ID:
NCT04178993
Status:
COMPLETED
Last Update Posted:
2023-01-09
First Post:
2019-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D008694', 'term': 'Methamphetamine'}, {'id': 'D008774', 'term': 'Methylphenidate'}, {'id': 'D007785', 'term': 'Lactose'}, {'id': 'D000068736', 'term': 'Duloxetine Hydrochloride'}], 'ancestors': [{'id': 'D000662', 'term': 'Amphetamines'}, {'id': 'D010627', 'term': 'Phenethylamines'}, {'id': 'D005021', 'term': 'Ethylamines'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D010648', 'term': 'Phenylacetates'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D010880', 'term': 'Piperidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D004187', 'term': 'Disaccharides'}, {'id': 'D009844', 'term': 'Oligosaccharides'}, {'id': 'D011134', 'term': 'Polysaccharides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D000073893', 'term': 'Sugars'}, {'id': 'D013876', 'term': 'Thiophenes'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'crush2@uky.edu', 'phone': '8592575388', 'title': 'Dr. Craig Rush, Ph.D.', 'organization': 'University of Kentucky'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Assessed during 4.5 weeks of inpatient study.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 2, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Active Comparator: Duloxetine (60 mg)', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 2, 'seriousNumAtRisk': 4, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Elevated Heart Rate', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 4, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Elevated Blood Pressure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 4, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0.29'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine (60 mg)', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0mg)', 'categories': [{'measurements': [{'value': '0', 'spread': '0', 'groupId': 'OG000'}, {'value': '0', 'spread': '0', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10mg)', 'categories': [{'measurements': [{'value': '3.33', 'spread': '5.77', 'groupId': 'OG000'}, {'value': '7.25', 'spread': '4.86', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20mg)', 'categories': [{'measurements': [{'value': '10', 'spread': '0', 'groupId': 'OG000'}, {'value': '9.75', 'spread': '0.50', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Following at least 4 days of maintenance on placebo during inpatient admission, up to 1 week', 'description': 'Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).', 'unitOfMeasure': 'Trials Completed', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Reinforcing Effects of Methamphetamine Following Methylphenidate (20 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine (60 mg)', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0mg)', 'categories': [{'measurements': [{'value': '0', 'spread': '0', 'groupId': 'OG000'}, {'value': '2.50', 'spread': '5.00', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10mg)', 'categories': [{'measurements': [{'value': '6.67', 'spread': '5.77', 'groupId': 'OG000'}, {'value': '7.00', 'spread': '4.69', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20mg)', 'categories': [{'measurements': [{'value': '8.00', 'spread': '3.46', 'groupId': 'OG000'}, {'value': '9.75', 'spread': '0.50', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week', 'description': 'Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).', 'unitOfMeasure': 'Trials Completed', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Reinforcing Effects of Methamphetamine Following Methylphenidate (40 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0mg)', 'categories': [{'measurements': [{'value': '1.67', 'spread': '2.89', 'groupId': 'OG000'}, {'value': '0', 'spread': '0', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10mg)', 'categories': [{'measurements': [{'value': '10', 'spread': '0', 'groupId': 'OG000'}, {'value': '5.00', 'spread': '5.77', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20mg)', 'categories': [{'measurements': [{'value': '10', 'spread': '0', 'groupId': 'OG000'}, {'value': '10', 'spread': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week', 'description': 'Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).', 'unitOfMeasure': 'Trials Completed', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Reinforcing Effects of Methamphetamine Following Methylphenidate (60 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine (60 mg)', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0mg)', 'categories': [{'measurements': [{'value': '2.33', 'spread': '4.04', 'groupId': 'OG000'}, {'value': '0', 'spread': '0', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10mg)', 'categories': [{'measurements': [{'value': '3.33', 'spread': '5.77', 'groupId': 'OG000'}, {'value': '7.50', 'spread': '5.00', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20mg)', 'categories': [{'measurements': [{'value': '10', 'spread': '0', 'groupId': 'OG000'}, {'value': '9.75', 'spread': '0.50', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week', 'description': 'Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).', 'unitOfMeasure': 'Trials Completed', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Heart Rate After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '77.67', 'spread': '16.17', 'groupId': 'OG000'}, {'value': '78.00', 'spread': '6.98', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '87.33', 'spread': '15.14', 'groupId': 'OG000'}, {'value': '77.25', 'spread': '15.37', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '81.33', 'spread': '12.01', 'groupId': 'OG000'}, {'value': '83.75', 'spread': '15.20', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Beats Per Minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Heart Rate After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '83.67', 'spread': '2.06', 'groupId': 'OG000'}, {'value': '76.00', 'spread': '8.41', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '84.33', 'spread': '8.50', 'groupId': 'OG000'}, {'value': '78.50', 'spread': '15.63', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '85.67', 'spread': '8.74', 'groupId': 'OG000'}, {'value': '89.50', 'spread': '16.90', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Beats Per Minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Heart Rate After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '85.00', 'spread': '13.08', 'groupId': 'OG000'}, {'value': '91.25', 'spread': '23.47', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '89.67', 'spread': '10.21', 'groupId': 'OG000'}, {'value': '87.75', 'spread': '17.50', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '87.67', 'spread': '12.86', 'groupId': 'OG000'}, {'value': '87.00', 'spread': '15.08', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Beats Per Minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Heart Rate After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '87.33', 'spread': '15.28', 'groupId': 'OG000'}, {'value': '88.00', 'spread': '19.11', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '83.67', 'spread': '11.72', 'groupId': 'OG000'}, {'value': '87.50', 'spread': '10.50', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '99.67', 'spread': '10.69', 'groupId': 'OG000'}, {'value': '88.00', 'spread': '19.36', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Beats Per Minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '132.67', 'spread': '2.89', 'groupId': 'OG000'}, {'value': '128.75', 'spread': '16.58', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '133.00', 'spread': '13.45', 'groupId': 'OG000'}, {'value': '131.00', 'spread': '11.83', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '132.67', 'spread': '5.03', 'groupId': 'OG000'}, {'value': '144.25', 'spread': '14.08', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Millimeter of Mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '129.67', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '124.25', 'spread': '25.02', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '131.67', 'spread': '18.61', 'groupId': 'OG000'}, {'value': '128.00', 'spread': '17.22', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '130.33', 'spread': '13.20', 'groupId': 'OG000'}, {'value': '132.75', 'spread': '15.95', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Millimeter of Mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '133.33', 'spread': '2.08', 'groupId': 'OG000'}, {'value': '129.75', 'spread': '11.47', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '129.00', 'spread': '12.77', 'groupId': 'OG000'}, {'value': '132.25', 'spread': '15.41', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '130.00', 'spread': '10.44', 'groupId': 'OG000'}, {'value': '139.25', 'spread': '11.67', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Millimeter of Mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '139.00', 'spread': '4.00', 'groupId': 'OG000'}, {'value': '127.00', 'spread': '15.06', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '138.67', 'spread': '11.59', 'groupId': 'OG000'}, {'value': '129.75', 'spread': '14.97', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '139.67', 'spread': '3.06', 'groupId': 'OG000'}, {'value': '135.25', 'spread': '15.39', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Millimeter of Mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '80.00', 'spread': '3.00', 'groupId': 'OG000'}, {'value': '78.50', 'spread': '7.77', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '82.33', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '83.75', 'spread': '9.54', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '87.33', 'spread': '5.51', 'groupId': 'OG000'}, {'value': '86.25', 'spread': '7.89', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Millimeter of Mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '81.67', 'spread': '4.51', 'groupId': 'OG000'}, {'value': '74.50', 'spread': '10.02', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '85.33', 'spread': '8.50', 'groupId': 'OG000'}, {'value': '83.25', 'spread': '11.03', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '83.00', 'spread': '3.61', 'groupId': 'OG000'}, {'value': '85.00', 'spread': '7.96', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Millimeter of Mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '78.00', 'spread': '2.65', 'groupId': 'OG000'}, {'value': '81.00', 'spread': '9.56', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '84.67', 'spread': '5.51', 'groupId': 'OG000'}, {'value': '82.25', 'spread': '8.10', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '84.67', 'spread': '6.51', 'groupId': 'OG000'}, {'value': '85.00', 'spread': '6.06', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Millimeter of Mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '82.67', 'spread': '5.51', 'groupId': 'OG000'}, {'value': '82.25', 'spread': '5.74', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '81.67', 'spread': '8.08', 'groupId': 'OG000'}, {'value': '82.25', 'spread': '7.93', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '88.33', 'spread': '4.73', 'groupId': 'OG000'}, {'value': '84.25', 'spread': '10.37', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Millimeter of Mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Temperature After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '98.10', 'spread': '0.26', 'groupId': 'OG000'}, {'value': '98.45', 'spread': '0.10', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '98.23', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '98.48', 'spread': '0.21', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '98.40', 'spread': '0.36', 'groupId': 'OG000'}, {'value': '98.48', 'spread': '0.19', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Degrees Fahrenheit', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Temperature After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '98.37', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '98.50', 'spread': '0.08', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '98.10', 'spread': '0.36', 'groupId': 'OG000'}, {'value': '98.75', 'spread': '0.26', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '98.27', 'spread': '0.32', 'groupId': 'OG000'}, {'value': '98.35', 'spread': '0.10', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Degrees Fahrenheit', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Temperature After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '98.17', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '98.60', 'spread': '0.22', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '98.13', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '98.65', 'spread': '0.17', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '98.43', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '98.55', 'spread': '0.26', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Degrees Fahrenheit', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Temperature After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methamphetamine (0 mg)', 'categories': [{'measurements': [{'value': '98.37', 'spread': '0.35', 'groupId': 'OG000'}, {'value': '98.65', 'spread': '0.17', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (10 mg)', 'categories': [{'measurements': [{'value': '98.43', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '98.65', 'spread': '0.06', 'groupId': 'OG001'}]}]}, {'title': 'Methamphetamine (20 mg)', 'categories': [{'measurements': [{'value': '98.47', 'spread': '0.35', 'groupId': 'OG000'}, {'value': '98.58', 'spread': '0.10', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)', 'unitOfMeasure': 'Degrees Fahrenheit', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (0 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '1.33', 'spread': '1.53', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '1.50', 'spread': '3.00', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '1.67', 'spread': '2.89', 'groupId': 'OG000'}, {'value': '1.50', 'spread': '3.00', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '2.25', 'spread': '4.50', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '2.50', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (0 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '22.33', 'spread': '35.28', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '1.00', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '3.00', 'spread': '5.20', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '4.33', 'spread': '6.66', 'groupId': 'OG000'}, {'value': '12.50', 'spread': '23.04', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '0.33', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '2.25', 'spread': '4.50', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '15.67', 'spread': '14.29', 'groupId': 'OG000'}, {'value': '18.25', 'spread': '36.50', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '15.33', 'spread': '24.83', 'groupId': 'OG000'}, {'value': '25.50', 'spread': '34.84', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '23.00', 'spread': '38.97', 'groupId': 'OG000'}, {'value': '22.25', 'spread': '35.98', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '46.33', 'spread': '45.06', 'groupId': 'OG000'}, {'value': '23.50', 'spread': '32.25', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '7.00', 'spread': '9.54', 'groupId': 'OG000'}, {'value': '11.50', 'spread': '21.05', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '11.33', 'spread': '19.63', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '21.33', 'spread': '36.09', 'groupId': 'OG000'}, {'value': '14.25', 'spread': '18.15', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '33.67', 'spread': '57.45', 'groupId': 'OG000'}, {'value': '15.00', 'spread': '15.10', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '10.67', 'spread': '18.48', 'groupId': 'OG000'}, {'value': '8.25', 'spread': '11.32', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '9.33', 'spread': '16.17', 'groupId': 'OG000'}, {'value': '12.00', 'spread': '14.28', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '12.67', 'spread': '20.21', 'groupId': 'OG000'}, {'value': '13.75', 'spread': '15.95', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '2.67', 'spread': '4.62', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '12.67', 'spread': '20.21', 'groupId': 'OG000'}, {'value': '16.00', 'spread': '19.13', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (0 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '10.33', 'spread': '17.90', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '0.33', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '20.00', 'spread': '32.05', 'groupId': 'OG000'}, {'value': '13.75', 'spread': '26.84', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '4.25', 'spread': '7.23', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '21.67', 'spread': '37.53', 'groupId': 'OG000'}, {'value': '16.00', 'spread': '25.77', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '35.67', 'spread': '55.72', 'groupId': 'OG000'}, {'value': '27.99', 'spread': '30.67', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '36.67', 'spread': '55.08', 'groupId': 'OG000'}, {'value': '20.50', 'spread': '33.81', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '50.00', 'spread': '47.70', 'groupId': 'OG000'}, {'value': '25.25', 'spread': '25.62', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '26.33', 'spread': '37.85', 'groupId': 'OG000'}, {'value': '12.00', 'spread': '23.34', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '32.67', 'spread': '56.58', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '38.33', 'spread': '53.41', 'groupId': 'OG000'}, {'value': '23.50', 'spread': '27.09', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '37.67', 'spread': '54.00', 'groupId': 'OG000'}, {'value': '26.25', 'spread': '27.56', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '31.33', 'spread': '54.27', 'groupId': 'OG000'}, {'value': '16.00', 'spread': '20.54', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '36.67', 'spread': '55.08', 'groupId': 'OG000'}, {'value': '20.50', 'spread': '22.55', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '30.33', 'spread': '44.77', 'groupId': 'OG000'}, {'value': '23.00', 'spread': '23.17', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '23.67', 'spread': '40.99', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '38.33', 'spread': '43.89', 'groupId': 'OG000'}, {'value': '24.50', 'spread': '24.08', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (20 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '3.00', 'spread': '2.65', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '1.00', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '1.67', 'spread': '2.89', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '1.67', 'spread': '2.08', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '4.00', 'spread': '6.93', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '1.50', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '1.67', 'spread': '2.89', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '4.00', 'spread': '6.93', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '3.00', 'spread': '5.20', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '3.33', 'spread': '5.77', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '1.50', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '8.00', 'spread': '13.86', 'groupId': 'OG000'}, {'value': '1.00', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '11.67', 'spread': '20.21', 'groupId': 'OG000'}, {'value': '1.50', 'spread': '3.00', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '2.67', 'spread': '4.62', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '1.50', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '2.33', 'spread': '4.04', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '4.67', 'spread': '8.08', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '7.67', 'spread': '13.28', 'groupId': 'OG000'}, {'value': '1.50', 'spread': '3.00', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '4.67', 'spread': '8.08', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '4.33', 'spread': '7.51', 'groupId': 'OG000'}, {'value': '1.50', 'spread': '3.00', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '4.00', 'spread': '6.93', 'groupId': 'OG000'}, {'value': '1.50', 'spread': '3.00', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '2.67', 'spread': '4.62', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '3.67', 'spread': '6.35', 'groupId': 'OG000'}, {'value': '1.50', 'spread': '3.00', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (20 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '10.67', 'spread': '14.36', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '2.00', 'spread': '3.46', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '2.00', 'spread': '3.46', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '0.33', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '14.67', 'spread': '23.69', 'groupId': 'OG000'}, {'value': '13.75', 'spread': '26.18', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '22.00', 'spread': '38.11', 'groupId': 'OG000'}, {'value': '13.00', 'spread': '26.00', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '17.33', 'spread': '27.43', 'groupId': 'OG000'}, {'value': '16.25', 'spread': '23.30', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '33.33', 'spread': '57.74', 'groupId': 'OG000'}, {'value': '18.50', 'spread': '35.68', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '40.00', 'spread': '52.74', 'groupId': 'OG000'}, {'value': '21.75', 'spread': '34.25', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '15.00', 'spread': '23.39', 'groupId': 'OG000'}, {'value': '13.00', 'spread': '24.68', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '5.67', 'spread': '9.81', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '20.33', 'spread': '32.65', 'groupId': 'OG000'}, {'value': '11.75', 'spread': '22.19', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '35.33', 'spread': '56.01', 'groupId': 'OG000'}, {'value': '14.00', 'spread': '24.06', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '19.00', 'spread': '32.91', 'groupId': 'OG000'}, {'value': '3.00', 'spread': '6.00', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '21.67', 'spread': '37.53', 'groupId': 'OG000'}, {'value': '14.25', 'spread': '21.87', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '21.00', 'spread': '30.35', 'groupId': 'OG000'}, {'value': '9.75', 'spread': '15.59', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '6.33', 'spread': '10.12', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '16.00', 'spread': '19.92', 'groupId': 'OG000'}, {'value': '14.75', 'spread': '18.39', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (20 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '4.33', 'spread': '7.51', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '9.33', 'spread': '16.17', 'groupId': 'OG000'}, {'value': '1.00', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '3.33', 'spread': '5.77', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '1.67', 'spread': '2.89', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '22.67', 'spread': '37.54', 'groupId': 'OG000'}, {'value': '14.50', 'spread': '27.01', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '3.00', 'spread': '5.20', 'groupId': 'OG000'}, {'value': '3.50', 'spread': '5.20', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '33.33', 'spread': '57.74', 'groupId': 'OG000'}, {'value': '14.25', 'spread': '22.34', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '30.00', 'spread': '38.97', 'groupId': 'OG000'}, {'value': '24.50', 'spread': '25.75', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '45.67', 'spread': '50.56', 'groupId': 'OG000'}, {'value': '17.25', 'spread': '25.89', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '48.00', 'spread': '50.12', 'groupId': 'OG000'}, {'value': '24.75', 'spread': '28.37', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '16.67', 'spread': '23.39', 'groupId': 'OG000'}, {'value': '14.50', 'spread': '25.77', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '11.33', 'spread': '19.63', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '36.67', 'spread': '55.08', 'groupId': 'OG000'}, {'value': '19.75', 'spread': '22.97', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '47.33', 'spread': '50.21', 'groupId': 'OG000'}, {'value': '18.75', 'spread': '23.85', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '33.33', 'spread': '57.74', 'groupId': 'OG000'}, {'value': '12.75', 'spread': '15.65', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '33.33', 'spread': '57.74', 'groupId': 'OG000'}, {'value': '16.50', 'spread': '18.88', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '35.67', 'spread': '55.73', 'groupId': 'OG000'}, {'value': '14.25', 'spread': '12.45', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '6.33', 'spread': '10.12', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '36.33', 'spread': '55.16', 'groupId': 'OG000'}, {'value': '13.75', 'spread': '12.84', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (40 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '8.00', 'spread': '13.86', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '7.00', 'spread': '12.12', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '0.67', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '10.33', 'spread': '17.90', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '0.58', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '17.33', 'spread': '30.02', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '1.50', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '23.00', 'spread': '39.84', 'groupId': 'OG000'}, {'value': '1.00', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '6.67', 'spread': '11.55', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '7.67', 'spread': '13.28', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '17.33', 'spread': '30.02', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '16.33', 'spread': '28.29', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '2.50', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '8.00', 'spread': '13.86', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '10.67', 'spread': '18.48', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '2.50', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '8.33', 'spread': '14.43', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '2.50', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '6.33', 'spread': '10.97', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '7.00', 'spread': '12.12', 'groupId': 'OG000'}, {'value': '4.25', 'spread': '5.68', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (40 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '8.67', 'spread': '15.01', 'groupId': 'OG000'}, {'value': '5.50', 'spread': '11.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '5.33', 'spread': '9.24', 'groupId': 'OG000'}, {'value': '1.00', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '3.00', 'spread': '5.20', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '2.00', 'spread': '3.46', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '18.67', 'spread': '32.33', 'groupId': 'OG000'}, {'value': '13.75', 'spread': '24.86', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '2.00', 'spread': '2.65', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '2.50', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '30.00', 'spread': '51.96', 'groupId': 'OG000'}, {'value': '9.75', 'spread': '19.50', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '6.33', 'spread': '10.12', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '22.33', 'spread': '37.82', 'groupId': 'OG000'}, {'value': '20.25', 'spread': '26.56', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '33.00', 'spread': '54.58', 'groupId': 'OG000'}, {'value': '17.00', 'spread': '28.77', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '39.33', 'spread': '51.60', 'groupId': 'OG000'}, {'value': '17.25', 'spread': '28.04', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '20.00', 'spread': '33.78', 'groupId': 'OG000'}, {'value': '11.25', 'spread': '20.55', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '6.00', 'spread': '10.39', 'groupId': 'OG000'}, {'value': '2.25', 'spread': '4.50', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '31.33', 'spread': '51.69', 'groupId': 'OG000'}, {'value': '9.50', 'spread': '16.38', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '33.67', 'spread': '54.00', 'groupId': 'OG000'}, {'value': '15.00', 'spread': '24.18', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '30.00', 'spread': '51.96', 'groupId': 'OG000'}, {'value': '4.50', 'spread': '8.35', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '30.33', 'spread': '51.68', 'groupId': 'OG000'}, {'value': '10.25', 'spread': '15.48', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '31.33', 'spread': '51.68', 'groupId': 'OG000'}, {'value': '9.25', 'spread': '13.52', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '3.67', 'spread': '6.35', 'groupId': 'OG000'}, {'value': '2.50', 'spread': '4.36', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '30.33', 'spread': '49.94', 'groupId': 'OG000'}, {'value': '11.50', 'spread': '12.12', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (40 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '1.33', 'spread': '2.31', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '0.33', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '2.50', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '25.33', 'spread': '39.55', 'groupId': 'OG000'}, {'value': '15.50', 'spread': '27.01', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '2.33', 'spread': '4.04', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '1.50', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '33.00', 'spread': '54.58', 'groupId': 'OG000'}, {'value': '14.75', 'spread': '29.50', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '7.00', 'spread': '12.12', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '2.50', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '28.00', 'spread': '41.68', 'groupId': 'OG000'}, {'value': '24.75', 'spread': '27.22', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '38.00', 'spread': '54.15', 'groupId': 'OG000'}, {'value': '21.25', 'spread': '27.71', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '41.67', 'spread': '51.81', 'groupId': 'OG000'}, {'value': '23.75', 'spread': '26.74', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '12.33', 'spread': '20.50', 'groupId': 'OG000'}, {'value': '15.00', 'spread': '26.77', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '5.33', 'spread': '9.24', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '31.67', 'spread': '48.85', 'groupId': 'OG000'}, {'value': '23.25', 'spread': '26.89', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '34.33', 'spread': '49.33', 'groupId': 'OG000'}, {'value': '24.75', 'spread': '26.29', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '29.00', 'spread': '49.37', 'groupId': 'OG000'}, {'value': '6.75', 'spread': '11.59', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '28.00', 'spread': '47.63', 'groupId': 'OG000'}, {'value': '20.50', 'spread': '22.22', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '35.00', 'spread': '48.545', 'groupId': 'OG000'}, {'value': '22.75', 'spread': '22.01', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '12.00', 'spread': '10.82', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '33.67', 'spread': '49.66', 'groupId': 'OG000'}, {'value': '19.50', 'spread': '20.24', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (60 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '12.33', 'spread': '21.36', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '15.33', 'spread': '26.56', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '14.00', 'spread': '24.25', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '32.33', 'spread': '50.06', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '31.00', 'spread': '48.59', 'groupId': 'OG000'}, {'value': '3.00', 'spread': '4.24', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '9.00', 'spread': '15.59', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '14.33', 'spread': '24.83', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '24.00', 'spread': '41.57', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '29.67', 'spread': '47.96', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '1.00', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '13.33', 'spread': '23.09', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '12.00', 'spread': '20.78', 'groupId': 'OG000'}, {'value': '2.00', 'spread': '2.45', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '13.67', 'spread': '23.67', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '1.50', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '3.00', 'spread': '5.20', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '15.33', 'spread': '26.56', 'groupId': 'OG000'}, {'value': '3.50', 'spread': '5.74', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (60 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '5.00', 'spread': '6.24', 'groupId': 'OG000'}, {'value': '1.00', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '4.67', 'spread': '8.08', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '29.00', 'spread': '50.23', 'groupId': 'OG000'}, {'value': '11.00', 'spread': '18.74', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '3.75', 'spread': '3.77', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '28.33', 'spread': '49.07', 'groupId': 'OG000'}, {'value': '11.75', 'spread': '16.50', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '3.67', 'spread': '6.35', 'groupId': 'OG000'}, {'value': '2.00', 'spread': '4.00', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '25.00', 'spread': '43.30', 'groupId': 'OG000'}, {'value': '23.00', 'spread': '23.17', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '36.00', 'spread': '54.74', 'groupId': 'OG000'}, {'value': '18.00', 'spread': '23.19', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '33.33', 'spread': '57.74', 'groupId': 'OG000'}, {'value': '23.75', 'spread': '23.89', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '14.67', 'spread': '25.40', 'groupId': 'OG000'}, {'value': '9.50', 'spread': '16.44', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '5.33', 'spread': '9.24', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '33.00', 'spread': '52.83', 'groupId': 'OG000'}, {'value': '17.25', 'spread': '18.19', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '32.67', 'spread': '55.72', 'groupId': 'OG000'}, {'value': '23.75', 'spread': '23.30', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '27.33', 'spread': '47.34', 'groupId': 'OG000'}, {'value': '10.75', 'spread': '21.50', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '27.00', 'spread': '46.77', 'groupId': 'OG000'}, {'value': '15.75', 'spread': '16.58', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '25.33', 'spread': '43.88', 'groupId': 'OG000'}, {'value': '20.25', 'spread': '18.37', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '4.67', 'spread': '8.08', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '24.67', 'spread': '41.86', 'groupId': 'OG000'}, {'value': '20.75', 'spread': '18.39', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (60 mg) Maintenance.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Sluggish/Fatigued/Lazy', 'categories': [{'measurements': [{'value': '6.67', 'spread': '11.55', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Restless', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '1.89', 'groupId': 'OG001'}]}]}, {'title': 'Nervous/Anxious', 'categories': [{'measurements': [{'value': '0.33', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Nauseated/Queasy/Sick to Stomach', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Talkative/Friendly', 'categories': [{'measurements': [{'value': '29.33', 'spread': '50.23', 'groupId': 'OG000'}, {'value': '18.25', 'spread': '31.94', 'groupId': 'OG001'}]}]}, {'title': 'Irregular/Racing Heartbeat', 'categories': [{'measurements': [{'value': '30.67', 'spread': '53.12', 'groupId': 'OG000'}, {'value': '1.00', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Euphoric', 'categories': [{'measurements': [{'value': '32.33', 'spread': '56.00', 'groupId': 'OG000'}, {'value': '18.00', 'spread': '35.34', 'groupId': 'OG001'}]}]}, {'title': 'Shaky/Jittery', 'categories': [{'measurements': [{'value': '2.00', 'spread': '3.46', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.50', 'groupId': 'OG001'}]}]}, {'title': 'Active/Alert/Energetic', 'categories': [{'measurements': [{'value': '37.33', 'spread': '53.46', 'groupId': 'OG000'}, {'value': '21.50', 'spread': '29.92', 'groupId': 'OG001'}]}]}, {'title': 'Will Pay For', 'categories': [{'measurements': [{'value': '34.00', 'spread': '57.17', 'groupId': 'OG000'}, {'value': '18.75', 'spread': '32.31', 'groupId': 'OG001'}]}]}, {'title': 'Will Take Again', 'categories': [{'measurements': [{'value': '37.67', 'spread': '54.04', 'groupId': 'OG000'}, {'value': '21.50', 'spread': '30.49', 'groupId': 'OG001'}]}]}, {'title': 'Performance Improved', 'categories': [{'measurements': [{'value': '22.00', 'spread': '33.05', 'groupId': 'OG000'}, {'value': '18.75', 'spread': '33.00', 'groupId': 'OG001'}]}]}, {'title': 'Performance Impaired', 'categories': [{'measurements': [{'value': '10.33', 'spread': '17.90', 'groupId': 'OG000'}, {'value': '13.50', 'spread': '27.00', 'groupId': 'OG001'}]}]}, {'title': 'Stimulated', 'categories': [{'measurements': [{'value': '36.00', 'spread': '53.73', 'groupId': 'OG000'}, {'value': '20.25', 'spread': '32.57', 'groupId': 'OG001'}]}]}, {'title': 'Like Drug', 'categories': [{'measurements': [{'value': '36.33', 'spread': '54.31', 'groupId': 'OG000'}, {'value': '21.50', 'spread': '31.72', 'groupId': 'OG001'}]}]}, {'title': 'Rush', 'categories': [{'measurements': [{'value': '35.67', 'spread': '53.35', 'groupId': 'OG000'}, {'value': '2.50', 'spread': '5.00', 'groupId': 'OG001'}]}]}, {'title': 'High', 'categories': [{'measurements': [{'value': '37.00', 'spread': '54.03', 'groupId': 'OG000'}, {'value': '20.25', 'spread': '27.89', 'groupId': 'OG001'}]}]}, {'title': 'Good Effects', 'categories': [{'measurements': [{'value': '39.00', 'spread': '53.23', 'groupId': 'OG000'}, {'value': '20.25', 'spread': '27.93', 'groupId': 'OG001'}]}]}, {'title': 'Bad Effects', 'categories': [{'measurements': [{'value': '9.67', 'spread': '16.74', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}]}]}, {'title': 'Any Effect', 'categories': [{'measurements': [{'value': '38.00', 'spread': '53.11', 'groupId': 'OG000'}, {'value': '19.25', 'spread': '24.78', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.', 'unitOfMeasure': 'Millimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Attentional Bias', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine (60 mg)', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methylphenidate (0mg)', 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.07', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (20mg)', 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '0.13', 'spread': '0.09', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (40mg)', 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.05', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (60mg)', 'categories': [{'measurements': [{'value': '0.12', 'spread': '0.11', 'groupId': 'OG000'}, {'value': '0.12', 'spread': '0.06', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '12 sessions over approximately 4.5 weeks', 'description': 'Subjects will complete an attentional bias task. The number of inhibitory failures (i.e., commission errors) to "no-go" targets following methamphetamine-related stimuli will be used to evaluate attentional bias (range 0 - 1: greater values represent greater number of errors committed). Commission errors are when you response (i.e., press the corresponding key on a computer) when you were instructed not to respond.', 'unitOfMeasure': 'Proportion of Responses', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Snaith-Hamilton-Pleasure Scale to Measure Anhedonia (Inability to Experience Pleasure)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine (60 mg)', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methylphenidate (0 mg)', 'categories': [{'measurements': [{'value': '44.33', 'spread': '8.33', 'groupId': 'OG000'}, {'value': '51.25', 'spread': '6.60', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (20 mg)', 'categories': [{'measurements': [{'value': '44.00', 'spread': '3.46', 'groupId': 'OG000'}, {'value': '52.75', 'spread': '4.72', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (40 mg)', 'categories': [{'measurements': [{'value': '44.33', 'spread': '5.51', 'groupId': 'OG000'}, {'value': '54.00', 'spread': '2.45', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (60 mg)', 'categories': [{'measurements': [{'value': '44.67', 'spread': '5.88', 'groupId': 'OG000'}, {'value': '53.00', 'spread': '6.00', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '4 times over approximately 4.5 weeks', 'description': 'A 14-item Snaith-Hamilton-Pleasure Scale covers four domains of pleasure response (interest/pastimes, social interaction, sensory experience and food/drink) with higher scores representing less anhedonia. Scores range from 0 to 56 units: lower scores representing greater anhedonia.', 'unitOfMeasure': 'Units on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Delay Discounting for Methamphetamine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine (60 mg)', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methylphenidate (0mg)', 'categories': [{'measurements': [{'value': '-1.40', 'spread': '1.63', 'groupId': 'OG000'}, {'value': '-1.31', 'spread': '0.72', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (20mg)', 'categories': [{'measurements': [{'value': '-1.04', 'spread': '1.10', 'groupId': 'OG000'}, {'value': '-1.27', 'spread': '0.49', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (40mg)', 'categories': [{'measurements': [{'value': '-1.45', 'spread': '1.63', 'groupId': 'OG000'}, {'value': '-1.15', 'spread': '0.33', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (60mg)', 'categories': [{'measurements': [{'value': '-1.17', 'spread': '1.91', 'groupId': 'OG000'}, {'value': '-1.04', 'spread': '0.43', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '4 sessions over approximately 4.5 weeks', 'description': 'Subjects will complete a delay discounting task in 4 sessions following 4 days of medication maintenance. Subjects are presented a series of hypothetical choices between a smaller amount of methamphetamine offered "now" or a larger amount of methamphetamine offered a later times in the future (e.g., 4 hours, a day, 3 weeks). The discounting rate, \'k\', is calculated and log10-transformed. Greater values of log-transformed \'k\' correspond with greater rates of discounting (i.e., preference for smaller reinforcer provided now rather than larger, delayed reinforcers \\[e.g., smaller amount of methamphetamine given now as opposed to a larger amount given later\\]). The units for discounting rates are theoretical and not linked to a physical dimension (e.g., number of button presses) and the range is theoretically not bound (i.e., negative infinity to positive infinity).', 'unitOfMeasure': 'log(k)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Delay Discounting for Money', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'OG001', 'title': 'Active Comparator: Duloxetine (60 mg)', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'classes': [{'title': 'Methylphenidate (0mg)', 'categories': [{'measurements': [{'value': '-1.40', 'spread': '1.63', 'groupId': 'OG000'}, {'value': '-1.29', 'spread': '0.76', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (20mg)', 'categories': [{'measurements': [{'value': '-1.40', 'spread': '1.63', 'groupId': 'OG000'}, {'value': '-1.37', 'spread': '0.58', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (40mg)', 'categories': [{'measurements': [{'value': '-1.45', 'spread': '1.63', 'groupId': 'OG000'}, {'value': '-1.15', 'spread': '0.33', 'groupId': 'OG001'}]}]}, {'title': 'Methylphenidate (60mg)', 'categories': [{'measurements': [{'value': '-1.48', 'spread': '1.43', 'groupId': 'OG000'}, {'value': '-1.04', 'spread': '0.43', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '4 sessions over approximately 4.5 weeks', 'description': 'Subjects will complete a delay discounting task in 4 sessions following 4 days of medication maintenance. Subjects are presented a series of hypothetical choices between a smaller sum of money offered "now" or a larger sum of money offered a later times in the future (e.g., 4 hours, a day, 3 weeks). The discounting rate, \'k\', is calculated and log10-transformed. Greater values of log-transformed \'k\' correspond with greater rates of discounting (i.e., preference for smaller reinforcer provided now rather than larger, delayed reinforcers \\[e.g., smaller sum of money given now as opposed to a larger sum given later\\]). The units for discounting rates are theoretical and not linked to a physical dimension (e.g., number of button presses) and the range is theoretically not bound (i.e., negative infinity to positive infinity).', 'unitOfMeasure': 'log(k)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'FG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.'}, {'id': 'BG001', 'title': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.\n\nMethamphetamine: In each arm, subjects will receive doses of methamphetamine.\n\nMethylphenidate: In each arm, subjects will receive methylphenidate capsules.\n\nPlacebo oral capsule: In each arm, subjects will receive placebo capsules.\n\nDuloxetine: Subjects will receive duloxetine capsules in the duloxetine arm.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '38', 'spread': '13.08', 'groupId': 'BG000'}, {'value': '41.5', 'spread': '13.11', 'groupId': 'BG001'}, {'value': '39.75', 'spread': '11.07', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2019-07-08', 'size': 11334146, 'label': 'Study Protocol, Statistical Analysis Plan, and Informed Consent Form', 'hasIcf': True, 'hasSap': True, 'filename': 'Prot_SAP_ICF_001.pdf', 'typeAbbrev': 'Prot_SAP_ICF', 'uploadDate': '2022-11-15T08:30', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'FACTORIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 8}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-09-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-12', 'completionDateStruct': {'date': '2021-05-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-12-12', 'studyFirstSubmitDate': '2019-08-09', 'resultsFirstSubmitDate': '2022-09-23', 'studyFirstSubmitQcDate': '2019-11-25', 'lastUpdatePostDateStruct': {'date': '2023-01-09', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2022-12-12', 'studyFirstPostDateStruct': {'date': '2019-11-26', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-01-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-05-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Attentional Bias', 'timeFrame': '12 sessions over approximately 4.5 weeks', 'description': 'Subjects will complete an attentional bias task. The number of inhibitory failures (i.e., commission errors) to "no-go" targets following methamphetamine-related stimuli will be used to evaluate attentional bias (range 0 - 1: greater values represent greater number of errors committed). Commission errors are when you response (i.e., press the corresponding key on a computer) when you were instructed not to respond.'}, {'measure': 'Snaith-Hamilton-Pleasure Scale to Measure Anhedonia (Inability to Experience Pleasure)', 'timeFrame': '4 times over approximately 4.5 weeks', 'description': 'A 14-item Snaith-Hamilton-Pleasure Scale covers four domains of pleasure response (interest/pastimes, social interaction, sensory experience and food/drink) with higher scores representing less anhedonia. Scores range from 0 to 56 units: lower scores representing greater anhedonia.'}, {'measure': 'Delay Discounting for Methamphetamine', 'timeFrame': '4 sessions over approximately 4.5 weeks', 'description': 'Subjects will complete a delay discounting task in 4 sessions following 4 days of medication maintenance. Subjects are presented a series of hypothetical choices between a smaller amount of methamphetamine offered "now" or a larger amount of methamphetamine offered a later times in the future (e.g., 4 hours, a day, 3 weeks). The discounting rate, \'k\', is calculated and log10-transformed. Greater values of log-transformed \'k\' correspond with greater rates of discounting (i.e., preference for smaller reinforcer provided now rather than larger, delayed reinforcers \\[e.g., smaller amount of methamphetamine given now as opposed to a larger amount given later\\]). The units for discounting rates are theoretical and not linked to a physical dimension (e.g., number of button presses) and the range is theoretically not bound (i.e., negative infinity to positive infinity).'}, {'measure': 'Delay Discounting for Money', 'timeFrame': '4 sessions over approximately 4.5 weeks', 'description': 'Subjects will complete a delay discounting task in 4 sessions following 4 days of medication maintenance. Subjects are presented a series of hypothetical choices between a smaller sum of money offered "now" or a larger sum of money offered a later times in the future (e.g., 4 hours, a day, 3 weeks). The discounting rate, \'k\', is calculated and log10-transformed. Greater values of log-transformed \'k\' correspond with greater rates of discounting (i.e., preference for smaller reinforcer provided now rather than larger, delayed reinforcers \\[e.g., smaller sum of money given now as opposed to a larger sum given later\\]). The units for discounting rates are theoretical and not linked to a physical dimension (e.g., number of button presses) and the range is theoretically not bound (i.e., negative infinity to positive infinity).'}], 'primaryOutcomes': [{'measure': 'Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance.', 'timeFrame': 'Following at least 4 days of maintenance on placebo during inpatient admission, up to 1 week', 'description': 'Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).'}, {'measure': 'Reinforcing Effects of Methamphetamine Following Methylphenidate (20 mg) Maintenance.', 'timeFrame': 'Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week', 'description': 'Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).'}, {'measure': 'Reinforcing Effects of Methamphetamine Following Methylphenidate (40 mg) Maintenance.', 'timeFrame': 'Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week', 'description': 'Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).'}, {'measure': 'Reinforcing Effects of Methamphetamine Following Methylphenidate (60 mg) Maintenance.', 'timeFrame': 'Following at least 4 days of maintenance on drug during inpatient admission, up to 1 week', 'description': 'Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement. Subjects sample a dose of methamphetamine (0, 10, or 20 mg) and then have the ten opportunities (e.g., trials) to "work" for a 1/10th of the sampled dose via clicking on a computer mouse (i.e., 10 completed trials is the full sampled dose).'}], 'secondaryOutcomes': [{'measure': 'Heart Rate After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Heart Rate After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Heart Rate After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Heart Rate After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Heart Rate (beats per minute) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Systolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Systolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Diastolic Blood Pressure After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Diastolic blood pressure (millimeter of mercury) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Temperature After Methamphetamine Administration Following Methylphenidate (0 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Temperature After Methamphetamine Administration Following Methylphenidate (20 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Temperature After Methamphetamine Administration Following Methylphenidate (40 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Temperature After Methamphetamine Administration Following Methylphenidate (60 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Oral temperature (degrees fahrenheit) is recorded following administration of methamphetamine. Data are presented as mean peak effect. Peak effect means the highest rated value following administration of methamphetamine (0, 10, and 20 mg)'}, {'measure': 'Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (0 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (0 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (0 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (20 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (20 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (20 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (40 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (40 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (40 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (0 mg) Administration Following Methylphenidate (60 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (10 mg) Administration Following Methylphenidate (60 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}, {'measure': 'Subjective Effects of Methamphetamine (20 mg) Administration Following Methylphenidate (60 mg) Maintenance.', 'timeFrame': 'Daily over approximately 1 week of inpatient stay.', 'description': 'Subjective effects (i.e., mood) of methamphetamine are recorded following administration. Data are presented as mean peak effect. Peak effect means the highest rated value (0 - 100 mm) following administration of methamphetamine.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Methamphetamine', 'Methylphenidate', 'Duloxetine Hydrochloride', 'Central Nervous System Stimulants', 'Physiological Effects of Drugs', 'Dopamine Uptake Inhibitors', 'Serotonin and Noradrenaline Reuptake Inhibitors', 'Membrane Transport Modulators', 'Neurotransmitter Agents', 'Dopamine Agents', 'Molecular Mechanisms of Pharmacological Action', 'Sensory System Agents', 'Peripheral Nervous System Agents', 'Vasoconstrictor Agents', 'Antidepressive Agents', 'Psychotropic Drugs'], 'conditions': ['Methamphetamine Use Disorder']}, 'descriptionModule': {'briefSummary': 'This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* recent use of inhaled (i.e., snorted), smoked or injected methamphetamine\n\nExclusion Criteria:\n\n* Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant.\n* Current or past histories of substance use that are deemed by the study physicians to interfere with study completion.\n* History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation.\n* Females not currently using effective birth control.\n* Contraindications to methamphetamine, methylphenidate, or duloxetine.'}, 'identificationModule': {'nctId': 'NCT04178993', 'briefTitle': 'Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]', 'organization': {'class': 'OTHER', 'fullName': 'University of Kentucky'}, 'officialTitle': 'A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder', 'orgStudyIdInfo': {'id': 'BED(IN):40'}, 'secondaryIdInfos': [{'id': 'R01DA047391', 'link': 'https://reporter.nih.gov/quickSearch/R01DA047391', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo Comparator: Placebo', 'description': 'Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.', 'interventionNames': ['Drug: Methamphetamine', 'Drug: Methylphenidate', 'Drug: Placebo oral capsule']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Active Comparator: Duloxetine', 'description': 'Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.', 'interventionNames': ['Drug: Methamphetamine', 'Drug: Methylphenidate', 'Drug: Placebo oral capsule', 'Drug: Duloxetine']}], 'interventions': [{'name': 'Methamphetamine', 'type': 'DRUG', 'otherNames': ['Metamfetamine'], 'description': 'In each arm, subjects will receive doses of methamphetamine.', 'armGroupLabels': ['Active Comparator: Duloxetine', 'Placebo Comparator: Placebo']}, {'name': 'Methylphenidate', 'type': 'DRUG', 'otherNames': ['Metadate®'], 'description': 'In each arm, subjects will receive methylphenidate capsules.', 'armGroupLabels': ['Active Comparator: Duloxetine', 'Placebo Comparator: Placebo']}, {'name': 'Placebo oral capsule', 'type': 'DRUG', 'otherNames': ['Lactose'], 'description': 'In each arm, subjects will receive placebo capsules.', 'armGroupLabels': ['Active Comparator: Duloxetine', 'Placebo Comparator: Placebo']}, {'name': 'Duloxetine', 'type': 'DRUG', 'otherNames': ['Cymbalta®'], 'description': 'Subjects will receive duloxetine capsules in the duloxetine arm.', 'armGroupLabels': ['Active Comparator: Duloxetine']}]}, 'contactsLocationsModule': {'locations': [{'zip': '40507', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'University of Kentucky', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '40536', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'University of Kentucky Medical Center', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Craig Rush', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute on Drug Abuse (NIDA)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Craig Rush', 'investigatorAffiliation': 'University of Kentucky'}}}}